AV-0222W

AV-0222W is a prophylactic vaccine candidate being developed by Aviex Technologies for the prevention of *Schistosomiasis mansoni* infection. The vaccine is based on the company's proprietary YS1646 platform, which utilizes a live attenuated strain of *Salmonella typhimurium* as a delivery vector for specific antigens. This platform is designed to stimulate both mucosal and systemic immune responses to prevent infection by the parasitic blood fluke. While the specific antigen targets for AV-0222W have not been publicly disclosed, the vaccine candidate is part of a broader pipeline of infectious disease vaccines utilizing the same bacterial vector technology.